AXDX Logo

Accelerate Diagnostics, Inc. (AXDX) 

NASDAQ
Market Cap
$47.36M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
181 of 776
Rank in Industry
27 of 100

Largest Insider Buys in Sector

AXDX Stock Price History Chart

AXDX Stock Performance

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic …

Insider Activity of Accelerate Diagnostics, Inc.

Over the last 12 months, insiders at Accelerate Diagnostics, Inc. have bought $219,998 and sold $87,223 worth of Accelerate Diagnostics, Inc. stock.

On average, over the past 5 years, insiders at Accelerate Diagnostics, Inc. have bought $10M and sold $471,910 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Strobeck Matthew (director) — $450,000. PATIENCE JOHN (director) — $74,997. MASSARANY HANY (director) — $49,998.

The last purchase of 16,666 shares for transaction amount of $24,999 was made by PATIENCE JOHN (director) on 2024‑01‑23.

List of Insider Buy and Sell Transactions, Accelerate Diagnostics, Inc.

2024-05-20SaleChief Technology Officer
361
0.0016%
$0.88$318+69.74%
2024-04-17SaleChief Executive Officer
26,735
0.1307%
$0.78$20,853+79.58%
2024-04-12SaleChief Executive Officer
26,545
0.1187%
$0.86$22,829+52.41%
2024-04-09SaleChief Technology Officer
13,984
0.0653%
$0.87$12,166+50.29%
2024-04-09SaleChief Financial Officer
13,296
0.0621%
$0.87$11,568+50.29%
2024-04-04SaleChief Executive Officer
15,887
0.0821%
$0.88$13,981+52.40%
2024-04-04SaleChief Technology Officer
978
0.0051%
$0.88$861+52.40%
2024-02-26SaleChief Financial Officer
350
0.0016%
$0.96$336+27.60%
2024-02-01SaleChief Executive Officer
494
0.0024%
$1.30$642-3.25%
2024-01-23Purchasedirector
16,666
0.1274%
$1.50$24,999-8.33%
2024-01-23Purchasedirector
100,000
0.7643%
$1.50$150,000-8.33%
2024-01-23Purchasedirector
16,666
0.1274%
$1.50$24,999-8.33%
2024-01-23Purchasedirector
13,333
0.1019%
$1.50$20,000-8.33%
2023-12-13SaleChief Executive Officer
739
0.0048%
$4.39$3,244-72.73%
2023-12-13SaleChief Financial Officer
97
0.0006%
$4.39$426-72.73%
2023-10-13SaleChief Executive Officer
734
0.0051%
$5.83$4,279-77.38%
2023-10-13SaleChief Financial Officer
96
0.0007%
$5.83$560-77.38%
2023-09-13SaleChief Executive Officer
733
0.0052%
$6.53$4,786-78.74%
2023-09-13SaleChief Financial Officer
96
0.0007%
$6.53$627-78.74%
2023-08-14SaleChief Executive Officer
751
0.0049%
$6.80$5,107-81.08%

Insider Historical Profitability

12.34%
PATIENCE JOHNdirector
453224
1.914%
$2.00110+24.1%
Strobeck Matthewdirector
120682
0.5096%
$2.0080+26.67%
Mertz Larry MichaelChief Technology Officer
81831
0.3456%
$2.0025<0.0001%
MASSARANY HANYdirector
24260
0.1025%
$2.0030<0.0001%
FRANCESCONI LOUISEdirector
20927
0.0884%
$2.0010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$1.83M8.371.85MNew+$1.83M0.01
Griffin Asset Management Inc$1.34M6.141.35M+11.03%+$133,184.650.16
Birchview Capital Lp$321,986.001.48325,239+44.4%+$98,999.810.02
The Vanguard Group$311,884.001.43315,034+2.74%+$8,313.04<0.0001
Geode Capital Management$129,300.000.59130,593+50.1%+$43,158.42<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.